Quick Answer
Spyre Therapeutics, Inc. reported Operating Income Loss of -$209.56 million for the year ending 2025.
- Spyre Therapeutics, Inc. showed a decrease of -0.5% in Operating Income Loss from 2024 to 2025.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Spyre Therapeutics, Inc.'s Operating Income Loss has declined by 2,253.6%.
- Historical annual values: Fiscal year 2025: -$209.56 million | Fiscal year 2024: -$208.57 million | Fiscal year 2023: -$242.30 million | Fiscal year 2022: -$84.78 million | Fiscal year 2021: -$65.65 million | Fiscal year 2020: -$81.48 million | Fiscal year 2019: -$80.33 million | Fiscal year 2018: -$45.46 million | Fiscal year 2017: -$27.68 million | Fiscal year 2016: -$21.91 million | Fiscal year 2015: -$11.32 million | Fiscal year 2014: -$8.90 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: